NOS3 and atherosclerosis: Asymmetric dimethylarginine (ADMA) increases endothelial cell dysfunction, contributing to the progression of atherosclerosis [4] by inhibiting endothelial nitric oxide synthase (eNOS) and reducing the production of nitric oxide (NO) in endothelial cells.